The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

Bristol Myers Squibb’s Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for lisocabtagene maraleucel (liso-cel) for adults with relapsed or ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Bristol Myers Squibb today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi ® in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary ...

Bristol Myers Squibb today announced the U.S. Food and Drug Administration has granted accelerated approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the ...

Bristol-Myers Squibb (NYSE:BMY) posted second-quarter earnings that surpassed analyst expectations, largely thanks to robust ...